GEN’s algorithm ranked the top locations that included many of the up-and-coming smaller clusters which are showing major advances. The European cluster building deploys the organizing principle of Subsidiarity, which increases the opportunity for accelerated growth. The closer the governing authority the faster decision process.
One notable example was Norway’s Oslo Cancer Cluster which will open an Innovation Park and Incubator in May 2o15. Their inclusion adds to the EU membership (now 64 members) and growing pipeline of cancer therapeutics developed through collaborations with global partners like those my firm continues to work on here in the States.
I believe we will continue to see growth in global collaborations and standardization of medical research, IP rights, research funding, Tech Transfer and commercialization. All of which is designed to bring new discoveries to the market quicker.
To read the GEN article and see the complete list of clusters: http://www.genengnews.com/insight-and-intelligence/top-10-european-biopharma-clusters/77900075/